Can propranolol be used to treat tremor in Parkinson disease (PD)?

Can Propranolol Be Used for Parkinsonism?

Yes, propranolol can be used as adjuvant therapy for tremor in Parkinson's disease, particularly when tremor persists despite levodopa optimization, though it is not FDA-approved for this indication and should be considered after dopaminergic therapy has been maximized.

Treatment Algorithm for Parkinsonian Tremor

First-Line Approach

Start with levodopa, which remains the most efficacious drug for PD tremor and should be the primary approach for troublesome tremor 1. Optimize the levodopa dose before considering adjuvant therapies.

When to Consider Propranolol

Add propranolol when:

• Tremor remains inadequately controlled despite optimized levodopa therapy
• Both resting tremor AND postural/action tremor components are present
• Patient has no contraindications (see below)

Evidence for Propranolol in PD Tremor

Efficacy Data

The most compelling recent evidence comes from a 2024 placebo-controlled crossover trial showing propranolol (40 mg single dose) significantly reduced tremor power (p = 0.02) and decreased tremor-related activity in the motor cortex 2. Importantly, this effect was context-independent—it worked regardless of stress levels, suggesting a general tremor-reducing mechanism at the cortical level.

An older but well-designed 1987 study demonstrated that long-acting propranolol 160 mg/day reduced:

• Resting tremor amplitude by 70%
• Postural tremor amplitude by 50%
• Clinical tremor scores significantly (p < 0.05)

Most patients in this study preferred propranolol and continued taking it, with no significant side effects reported 3.

Mechanism of Action

Propranolol appears to work by inhibiting tremor-related activity specifically in the primary motor cortex, rather than affecting the basal ganglia tremor generator 2. This explains why it can be effective as an adjunct even when dopaminergic therapy has plateaued.

Practical Prescribing

Dosing

• Start with long-acting propranolol 80-160 mg daily
• Can titrate up to 240 mg daily if needed and tolerated
• The 1987 study used 160 mg/day as the standard dose 3

What to Expect

• Propranolol improves both resting and postural tremor components 3, 1
• Effect is additive to levodopa, not a replacement
• Works best when tremor has both parkinsonian and action components

Critical Contraindications and Cautions

Absolute Contraindications (per FDA labeling)

• Bronchospastic lung disease (asthma, COPD)—can provoke severe bronchospasm 4
• Overt congestive heart failure
• Severe bradycardia or heart block

Special Precautions in PD Patients

Bradycardia risk is substantial: One study reported significant heart rate drops in 14 of 22 patients (64%), with one withdrawal due to heart rate falling to 56 bpm 5. This is particularly concerning in elderly PD patients who may already have autonomic dysfunction.

Monitor closely for:

• Heart rate (target >60 bpm)
• Blood pressure (can cause hypotension)
• Hypoglycemia masking—especially problematic if patient is diabetic 4
• Worsening heart failure symptoms

Drug Interactions

Propranolol increases warfarin bioavailability and prothrombin time—adjust anticoagulation monitoring accordingly 4.

Limitations and Alternative Considerations

Evidence Quality Issues

A 2003 Cochrane review found that most propranolol trials in PD had methodological flaws, with three of four studies not presenting first-arm data properly 5. However, the more recent 2024 neuroimaging study provides stronger mechanistic evidence 2.

When Propranolol Fails

If tremor remains refractory despite levodopa optimization plus propranolol:

• Consider clozapine (requires blood monitoring for agranulocytosis) 1
• Evaluate for deep brain stimulation or focused ultrasound as first-line surgical options 1

Not FDA-Approved for PD

The FDA label for propranolol lists approved indications as hypertension, angina, migraine prophylaxis, and hypertrophic subaortic stenosis—not Parkinson's disease 4. This is off-label use, though supported by clinical evidence.

Common Pitfalls to Avoid

1. Don't use propranolol as monotherapy—always optimize dopaminergic therapy first 1
2. Don't ignore cardiovascular screening—the high rate of bradycardia demands baseline ECG and heart rate monitoring 5
3. Don't confuse with essential tremor—while propranolol is highly effective for essential tremor, the evidence base and response rates differ in PD 6
4. Don't abruptly discontinue—can precipitate rebound hypertension or, in patients with hyperthyroidism, thyroid storm 4